Showing 20 of 27 recruiting trials for “MALT lymphoma”
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
👨⚕️ Gottfried von Keudell, MD, PhD, Beth Israel Deaconess Medical Center📍 1 site📅 Started Feb 2026View details ↗
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
👨⚕️ Shuhua yi, Hematology Hospital, Chinese Academy of Medical Sciences📍 14 sites📅 Started Jan 2026View details ↗
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RecruitingNCT06712459 ↗
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
👨⚕️ Luca Arcaini, MD, Fondazione IRCCS Policlinico San Matteo📍 7 sites📅 Started Oct 2025View details ↗
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Aug 2025View details ↗
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2025View details ↗
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
👨⚕️ Fei Li, professor, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Dec 2024View details ↗
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
RecruitingNCT06534463 ↗
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
👨⚕️ Bing Xu, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Jun 2024View details ↗
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →